Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, et al. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. J Clin Oncol 2024;42:2080-2093.
PMID: 38723227